BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
BioAge Labs, Inc.NASDAQ: BIOA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$22.15M, compared with -$12.64M a year earlier. Trailing-twelve-month EBITDA was -$89.21M.
Context
- EBITDA amounted to 886.0% of revenue in FY2025.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -$89.59M (-12.4%) for the fiscal year ending Dec 2026, a step up from the -16.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$22.15M+14.1% QoQ
- Last fiscal yearDec 2025
- -$79.7M-16.2% YoY
- LTMMar 2026
- -$89.21M-28.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -75.3% | -30.5% | +44.8 pp |
| 1 year | -16.2% | -12.4% | +3.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (79.7M) USD
- Year-over-year change
- -16.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (79.7M) | -16.2% |
| FY2024 | 2024-12-31 | (68.58M) | -22.7% |
| FY2023 | 2023-12-31 | (55.9M) | -42.0% |
| FY2022 | 2022-12-31 | (39.35M) | — |
EBITDA vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.4% is the 5th highest of 9, against a peer median of +1.3%.
- EBITDA amounts to 864.8% of revenue for BIOA, versus a peer median of 44.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$10.48M CAD | -79.6% | — | 3.4% | |
| LTM Mar 2026 | -$1.03M USD | — | — | 0.8% | |
| LTM Mar 2026 | -$9.96M USD | +38.2% | — | 23.8% | |
| LTM Mar 2026 | -$79.77M USD | -33.1% | — | 3956.7% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.21M USD | -28.4% | — | 864.8% |
| LTM Mar 2026 | -$100.08M USD | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -$160.41M USD | +32.7% | — | — | |
| LTM Mar 2026 | -$171.58M USD | -48.1% | — | — | |
| LTM Mar 2026 | -$179.89M USD | -30.1% | — | — | |
| LTM Mar 2026 | -CA$205.34M CAD | +57.2% | — | 65.7% | |
| Peer median (excluding BIOA) | — | +1.3% | — | 44.8% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 9M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 9M |
| Gross Margin | — | — | — | 100.0% |
| Research & Development | 30.52M | 33.89M | 59.04M | 73.97M |
| Selling, General & Admin | 9.45M | 14.51M | 19.16M | 27.81M |
| Operating Expenses | 39.97M | 48.4M | 78.19M | 101.78M |
| Depreciation & Amortization | 129K | 162K | 167K | 213K |
| EBITDA | (39.35M) | (55.9M) | (68.58M) | (79.7M) |
| EBITDA Margin | — | — | — | -886.0% |
| Operating Income | (39.97M) | (48.4M) | (78.19M) | (92.78M) |
| Operating Margin | — | — | — | -1031.5% |
| Interest Income | 465K | 2.43M | 9.63M | 13.09M |
| Interest Expense | 241K | 7.79M | 2.37M | 697K |
| Other Income / Expenses | 247K | (15.45M) | 7.09M | 12.18M |
| Income Before Tax | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Pre-Tax Margin | — | — | — | -896.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Net Margin | — | — | — | -896.1% |
| EPS (Basic) | (1.16) | (1.87) | (1.98) | (2.24) |
| EPS (Diluted) | (1.16) | (1.87) | (1.98) | (2.24) |
| Weighted Avg Shares | 34.17M | 34.2M | 35.85M | 35.93M |
| Weighted Avg Shares (Diluted) | 34.17M | 34.2M | 35.85M | 35.93M |
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.